About Us

A More Efficient Approach to Drug Development

RRD was founded in 2002 on a basic premise: Create an alternative approach to drug development that enables more efficient use of capital and accelerates an asset’s value inflection point.

Our Product Development Team (PDT) partnering model anticipated the shift in early drug development from large pharma to biotech and has a long track record of value creation. The model first defines the right strategy to optimize asset value through human proof-of-concept (hPOC) and then controls operational execution of that strategy for a more predictable achievement of value.

Our unmatched combination of expertise and experience spans the entire product development process to deliver the scientific input, strategic insight, program management, and operational excellence required to more rapidly achieve development milestones.

Leveraging the same PDT model and expertise, our subsidiary, ClearPath Development Company, streamlines development and drives asset value through tailored financing structures for in-licensed assets. Collaborating with venture capital and private equity, ClearPath provides a capital efficient, turn-key model, to accelerate development of assets with multiple exit options for innovators and investors at hPOC.

Record of value creation

Since our founding, we have added value to assets for our partners and through those 
partners, helped deliver new therapeutic options to patients in need. RRD has:

Helped partners achieve more than $2.5 billion in deal value through IPOs, acquisitions, licensing deals, and market approvals

Achieved multiple market approvals in collaboration with partners

Advanced more than 20 DevCo programs through hPOC

Evaluated hundreds of product opportunities and provided development leadership, management and execution of all program aspects

  • Due diligence
  • Strategic planning
  • Pre-IND through hPOC program execution

Provided development oversight for a private equity biopharma option fund investing close to $400 million in pipeline programs

  • In-licensed 17 assets for 21 indications
  • Created and managed 7 DevCo’s yielding 3 marketed products (cardiovascular, oncology, CNS) with a number of assets still in clinical development

RRD Leadership

RRD’s senior leadership provides development strategy and oversight for PDT partner programs.  The team includes former executives from biopharma, FDA, and CROs with experience across all stages of development, including most major product classes and therapeutic areas.

Leadership Team
Board of Directors